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Abstract
Background—Few studies have examined recent temporal trends in self-reported receipt of 
pelvic inflammatory disease (PID) treatment. We assessed trends in receipt of PID treatment and 
associated correlates using national survey data.
Methods—We used data from the National Survey of Family Growth, a multi-stage national 
probability survey of 15–44 year old women. We examined trends in self-reported receipt of PID 
treatment from 1995, 2002, to 2006–10. Additionally, we examined correlates of PID treatment in 
1995 and 2006–10 in bivariate and adjusted analyses.
Results—From 1995 to 2002, receipt of PID treatment significantly declined from 8.6% to 5.7% 
(p<.0001); however, there was no difference from 2002 to 2006–10 (5.0%, p=.16). In bivariate 
analyses, racial differences in PID treatment declined across time; in 2006–10, there was no 
significant difference between racial/ethnic groups (p=.22). Also in bivariate analyses, similar to 
1995, in 2006–10, some of the highest reports of receipt of PID treatment were women who were 
35–44 years old (5.6%), had an income less than 150% of poverty level (7.5%), had less than high 
school education (6.7%), douched (7.7%), had intercourse before age 15 (10.3%), and had 10 or 
more lifetime partners (8.0%). In adjusted analyses, differing from 1995, women at less than 150% 
of the poverty level were more likely (AOR=2.60, 95%CI 1.79–3.76) than women at 300% or 
more of the poverty level to have received PID treatment in 2006–10.
Conclusions—Receipt of PID treatment declined from 1995 to 2006–10 with the burden 
affecting women of lower socioeconomic status.
SHORT SUMMARY
Data from a national probability sample of reproductive-aged women found a decrease in receipt 
of treatment for pelvic inflammatory disease from 1995 to 2006–10 but treatment was highest 
among women with a lower socioeconomic status.
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Pelvic inflammatory disease (PID) has been associated with infertility and has been 
identified as a potential sequela of untreated sexually transmitted infections (STIs) such as 
chlamydia and gonorrhea [1–3]. A study reporting data from three national surveys found 
decreases in PID diagnosed in hospital and ambulatory visits from 1985 to 2001 [4]. 
Additionally, the study found that 91% of PID cases were diagnosed in ambulatory settings 
[4]. More recently, PID cases appeared to decline from 244,000 to 100,000 patient visits to 
physician offices for the condition from 2000 to 2009, respectively [5]. The cause of the 
apparent decline is unknown. Also, a substantial portion of PID cases may not be diagnosed 
as the symptoms may be mild or subclinical; therefore, established estimates for PID may be 
lower than true incidence. [6] In addition to infertility, the potential complications of PID 
include ectopic pregnancy, and chronic pelvic pain [5]. The medical cost per case of PID, 
including these complications, has been estimated to be about $3200 (2010 dollars). [7]
Given the substantial burden related to PID in women, several studies have examined the 
correlates or risk factors for PID. Correlates that have been frequently associated with PID 
across multiple studies include age (mixed findings) [6,8–10], younger age at first sexual 
intercourse [8–13], number of sex partners (multiple partners in a specific timeframe or a 
higher number of partners) [6,8–10], and a history of STIs [6,8–9,12–13]. Other factors 
associated with PID that have been identified in some studies are non-use of contraceptives 
including barrier methods [6,8,11–12], lower education level or socio-economic status [10–
12], and vaginal douching [8,12]. Finally, several studies have found disparities in PID 
incidence and prevalence by racial or ethnic groups. Specifically, these studies have found 
that black or non-white women are more likely to have PID than white women. [2,8–10,14–
15]
However, few studies have examined recent trends and correlates of PID in the United States 
(U.S.) [5]. Given the recently observed decreases in PID, it is important to examine 
correlates of PID over time. Therefore, the objectives of this study were to 1) examine 
temporal trends in self-reported receipt of PID treatment and 2) examine correlates of receipt 
of PID treatment in 1995 and 2006–10.
Methods
We used data from the National Survey of Family Growth (NSFG) a multi-stage national 
probability sample of men and women aged 15–44 years living in U.S. households. From 
1973 to 2002, NSFG was conducted periodically (i.e., interviews conducted over a period of 
several months every 3–7 years). From June 2006 to June 2010, NSFG switched to 
continuous administration, with interviews conducted throughout this time period. For this 
study, we used female data from the 1995, 2002, and 2006–10 NSFG. The design of the 
NSFG has been described in detail elsewhere [17–18]; however, sample sizes and response 
rates for female respondents were as follows: 1995 (n=10,847, response rate = 79%) [19], 
2002 (n=7,643, response rate = 80%) [20], and 2006–10 (n=12,279, response rate = 78%) 
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[21]. In all years, NSFG included over-samples of black and Hispanic women, and in 2002 
and 2006–10 also included over-samples of adolescents. NSFG was approved by the ethics 
review board at the National Center for Health Statistics and respondents provided informed 
consent (adolescents provided assent after parental consent).
We used data from the computer assisted personal-interview (CAPI) where highly trained 
female interviewers administer survey questions. Our outcome of interest – ever received 
treatment for PID – was defined using the following survey question: “Have you ever been 
treated for an infection in your fallopian tubes, womb, or ovaries, also called a pelvic 
infection, pelvic inflammatory disease, or P.I.D.?” We examined several demographic 
characteristics and sexual behaviors previously identified as predictors or correlates of PID. 
Demographic factors included in this study were race/ethnicity (Hispanic, non-Hispanic 
white, and non-Hispanic black), age (15–19, 20–24, 25–34, 35–44), current marital status 
(married to a male, cohabiting with a male partner, formerly married, never married/not 
cohabiting), highest education level (less than high school/no general educational 
development or GED, high school/GED, some college, Bachelor’s degree or higher), family 
income as percentage of federal poverty level (FPL), referred to as income-poverty ratio 
level (less than 150%, 150–299%, and 300% or higher), and region of country where the 
respondent resides (northeast, midwest, south, west). Sexual and related behaviors included 
were: used a vaginal douche regularly [1995] or in the past 12 months [2002 and 2006–10] 
(douching was recoded as yes, no), age at first vaginal intercourse (less than 15 years, 15–
17, 18–19, 20 years or older), and number of vaginal intercourse partners in lifetime 
(recoded [9] into the following categories: 1, 2–3, 4–9, 10 or more partners).
We used the SURVEY procedures in SAS (Release 9.2, SAS Institute, Cary, North Carolina) 
for all analyses to account for the multi-staged sampling procedures used by NSFG. Data 
were weighted to represent the U.S. female population aged 15–44 years in 1995, 2002, and 
2006–10. All analyses were limited to sexually experienced women (i.e., reported at least 
one vaginal intercourse partner in lifetime) and the three racial/ethnic groups for which we 
had large sample sizes or were oversampled – Hispanic, non-Hispanic white, and non-
Hispanic black. We conducted several analyses to examine trends in receipt of PID treatment 
and to examine correlates of PID treatment to determine if they changed over time. First, we 
used chi-square tests to compare differences in receipt of PID treatment overall and by race/
ethnicity across time (1995, 2002, and 2006–10). Next, we examined the relationship 
between demographic characteristics and sexual and related behaviors and receipt of PID 
treatment in 1995 and 2006–10, separately. As douching was not consistently measured over 
time, we did not merge data from different survey years into one analysis that included 
survey year as a correlate. We used chi-square tests for bivariate analyses and conducted 
separate adjusted logistic regression models for the two survey periods (1995, 2006–10). 
Given that the variables included in our analyses were found to be significantly associated 
with PID in previous research, we used all variables in the adjusted analyses.
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Trends in PID Treatment: 1995, 2002, 2006–10
We examined differences in the receipt of PID treatment overall and by race/ethnicity 
(Hispanic, non-Hispanic white, non-Hispanic black) and during the three time periods 
included in this study. Overall, receipt of PID treatment among sexually experienced women 
significantly declined from 8.6% in 1995 to 5.7% in 2002 (p<.0001) and then leveled off to 
5.0% in 2006–10 (p=.16). For 1995, we found significant differences in PID treatment 
among the three racial/ethnic groups with 11.6% of non-Hispanic black women, 8.7% of 
non-Hispanic white women, and 8.0% of Hispanic women reporting receipt of PID 
treatment in their lifetime (p<.001) (Figure 1). The racial/ethnic differences appeared to 
decline in 2002; however, a significant difference remained with 7.4% of non-Hispanic black 
women, 6.4% of non-Hispanic white women, and 5.1% of Hispanic women reporting receipt 
of PID treatment in their lifetime (p<.05). In 2006–10, there was no statistically significant 
differences in receipt of PID treatment by race/ethnicity (p=.22).
Correlates of PID Treatment: 1995 and 2006–10
In 1995, nearly all of the demographic characteristics and sexual behaviors that we 
examined had significant differences in receipt of PID treatment in bivariate analyses (Table 
1). For race/ethnicity (p<.001), age (p<.0001), and current marital status (p<.0001), women 
with the highest reports of receiving PID treatment were non-Hispanic black (11.6%), 35–44 
years old (10.5%), or formerly married (12.8%). Both socioeconomic status variables that 
we examined, education level (p<.0001) and poverty income level (p<.0001) were 
significantly associated with receipt of PID treatment with highest reports among women 
with less than a high school education (10.1%) or an income less than 150% of FPL 
(10.7%). Additionally, there were significant differences by U.S. Census region of residence 
with highest reports of receipt of PID treatment in the south (10.0%). Finally, all three sexual 
and related behaviors were significantly associated with receipt of PID treatment with 
highest reports among women who douched (12.1%, p<.0001), had first vaginal intercourse 
before age 15 years (12.5%, p<.0001), or had 10 or more lifetime vaginal intercourse 
partners (15.1%, p<.0001).
Similar patterns were found in bivariate analyses for the 2006–10 timeframe. Age (p=.04), 
current marital status (p<.01), education level (p<.0001), and poverty income level (p<.
0001) remained significant correlates of receipt of PID treatment with the highest reports 
among women who were 35–45 years old (5.6%), formerly married (8.0%), had less than a 
high school education (6.7%), or an income less than 150% of the FPL (7.5%). Conversely, 
although significant in 1995, there were no significant differences in receipt of PID 
treatment by race/ethnicity (p=.22) or region of the U.S. (p=.94) in 2006–10. Similar to 
1995, vaginal douching (p<.0001), younger age at first vaginal intercourse (p<.0001), and a 
higher number of lifetime vaginal intercourse partners (p<.0001) were significantly related 
to receipt of PID treatment in 2006–10 with highest reports among women who douched 
(7.7%), had first vaginal intercourse before age 15 years (10.3%), or had 10 or more lifetime 
vaginal sex partners (8.0%).
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Adjusted analyses: 1995 and 2006–10
All variables were entered into separate logistic regression models by the two survey 
periods. In 1995, two demographic variables remained significantly associated with receipt 
of PID treatment in adjusted analyses - age and education level. As compared to women 
aged 35–44 years, women aged 15–19 years (AOR = 0.43, 95%CI 0.25–0.71), 20–24 years 
(AOR = 0.64, 95%CI 0.47–0.86), 25–29 years (AOR = 0.61, 95%CI 0.47–0.80) and 30–34 
years (AOR = 0.76, 95%CI 0.61–0.96) were less likely to have received PID treatment. For 
education level, women having less than a high school diploma (AOR = 1.49, 95%CI 1.06–
2.11) and those with a high school diploma or GED (AOR = 1.32, 95%CI 1.02–1.70) had 
higher reports of receipt of PID treatment than women with a Bachelor’s degree or higher. 
All three sexual and related behaviors remained significant in adjusted analyses. Women 
who used a vaginal douche (AOR = 1.49, 95%CI 1.24–1.80), had first vaginal sex before age 
15 years (AOR = 1.59, 95%CI 1.12–2.27), and who had 4–9 partners (AOR = 1.67, 95%CI 
1.31–2.13) or 10 or more partners (AOR = 2.61, 95%CI 1.91–3.55) were more likely to 
report receipt of PID treatment than women who did not douche, had first vaginal sex at 20 
years or older, or had one lifetime vaginal sex partner, respectively.
Findings from the 2006–10 logistic regression analysis had some similarities but also had 
some key differences to findings from the 1995 analysis. Similar to 1995, women with less 
education [having less than a high school diploma (AOR = 1.95, 95%CI 1.14–3.35), a high 
school diploma or GED (AOR = 1.89, 95%CI 1.23–2.90, or some college (AOR = 2.27, 
95%CI 1.46–3.55)] were more likely to report receipt of PID treatment as compared to 
women with a Bachelor’s degree or higher. Also similar to 1995, women who douched 
(AOR = 1.33, 95%CI 1.01–1.75) were more likely as those who did not douche to report 
receipt of PID treatment in 2006–10. Additionally, women who had first vaginal sex before 
age 15 years (AOR = 2.57, 95%CI 1.36–4.85) were more likely to report receipt of PID 
treatment than women who had first vaginal sex at 20 years or older. Those who had 4–9 
partners (AOR = 1.76, 95%CI 1.03–3.00) or 10 or more partners (AOR = 2.09, 95%CI 1.20–
3.66) were more likely to report receipt of PID treatment than women who had one lifetime 
vaginal sex partner. Conversely, findings for age and poverty level income differed from 
1995 to 2006–10. In 2006–10, there was only one age-group (instead of four in 1995) 
affected by a significant difference for age – women who were 15–19 years old (AOR = 
0.38, 95%CI 0. 21–0.68) were less likely than women 35–44 years to report receipt of PID 
treatment. Additionally, women with an income less than 150% of the FPL (AOR = 2.60, 
95%CI 1.79–3.76) and 150–299% of FPL (AOR = 1.84, 95%CI 1.20–2.82) were more likely 
than women with an income 300% of the FPL or higher to report receipt of PID treatment.
Given that many women aged less than 22 years are in the process of continuing their 
education, we conducted post-hoc adjusted analyses on 22–44 year old women to confirm 
that our results for education would be similar when limited to this somewhat older 
subpopulation. In both 1995 and 2006–10, our findings for education were similar when 
examining 15–44 year old and 22–44 year old women.
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Trends in PID Treatment
Findings from this study demonstrate a significant decline in self-reported receipt of PID 
treatment among reproductive-aged women in the U.S. Extending earlier research on 
decreases in PID across time [4], we found a continued decline in receipt of PID treatment 
between 1995 and 2002; however, we found no difference between 2002 and 2006–10. 
Additionally, racial differences in PID diagnosis or treatment were frequently found in 
earlier research [2,8–10,14–15]. However, although we found a difference by race/ethnicity 
using bivariate analyses in 1995 and 2002, race/ethnicity was not a significant correlate of 
receipt of PID treatment in our multivariable analysis of 1995 data.
It is possible that the continued decline in receipt of PID treatment may be related to 
changes in STI rates, screening for STIs such as gonorrhea and chlamydia (e.g., through 
identification of asymptomatic cases), or in issues related to healthcare access. However, the 
number of reported cases of gonorrhea varied little during our study timeframe [5]. 
Additionally, reported chlamydia cases appeared to increase during this time; but, research 
suggests that this increase may be related to increases in screening coverage or 
improvements in laboratory test technology [22]. A randomized controlled trial of chlamydia 
screening found fewer cases of PID in women in the screening arm [23], and a more recent 
analysis of monthly medical insurance claims data for women with private health insurance 
found that higher screening rates for chlamydia and gonorrhea were associated with a 
decreased rate of PID four months later [24]. Additionally, chlamydia screening of 16–24 
year old women enrolled in commercial or Medicaid plans has consistently increased since 
2001 [25]. An analysis of 15–25 year old women in 2006–08 NSFG found that non-Hispanic 
black women were more likely than non-Hispanic white women to report receiving a 
chlamydia test [26]. Thus, improvements in chlamydia screening, including treatment of the 
infection that is often asymptomatic, may be related to the observed declines in PID 
treatment over time. Although it is possible that changes in healthcare access played a role in 
the decline in PID, a previous analysis of NSFG data found no relationship between health 
insurance mandates and infertility service use [27]. The percentage of uninsured in the U.S. 
did not appear to change from 1995 to 2007; however, there were slight shifts from private to 
public insurance coverage during this time [28]. Therefore, additional research is needed to 
determine if healthcare access issues such as type of insurance were related to the observed 
decreases in PID treatment.
Correlates of PID Treatment
In both timeframes, consistent with some previous research, receipt of PID treatment was 
related to douching [29] and sexual behaviors [8–9,12]; however, our analysis identified 
different patterns for age and poverty status across the two timeframes. In 2006–10, only 
adolescents were less likely than women 35–44 years old to have ever received treatment for 
PID whereas in 1995 all age groups were less likely to have received treatment for PID. It is 
possible that other factors such as a significant decrease in age disparities for reported cases 
of gonorrhea from 1981 to 2005 [30] and the increasing importance of socioeconomic status 
and PID treatment may have played a role in the changing age-related patterns over time. As 
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noted, socioeconomic status is an important predictor of PID treatment. In adjusted analyses, 
women whose education level was less than a Bachelor’s degree were more likely to report 
receipt of PID treatment in both timeframes; however, poverty level was only significant in 
2006–10, where women with lower household incomes were more likely to have received 
PID treatment.
There are some limitations to this study. First, our measure of receipt of PID treatment was 
subject to possible bias (e.g., recall and diagnosis biases). Diagnosis of PID can be difficult 
given that symptoms are similar to those of other reproductive health problems [6,31]. Also, 
one study found inconsistencies in PID diagnoses across healthcare providers in Australia, 
and authors speculated that it may be related to cases of PID missed by some doctors [32]. It 
is also possible that PID has become increasingly subclinical over time leading to a decrease 
in diagnoses. Another limitation is that we did not have a consistent measure of health 
insurance and healthcare access with appropriate timeframes across the datasets. There were 
limitations with our douching measure given different timeframe anchors and question 
wording used in 1995 and 2006–10. Additionally, there are limitations in adolescents’ 
knowledge about household income; therefore, our measure of poverty income level may be 
less valid for this sub-population. Finally, we did not include a measure of STI history 
because questions about chlamydia and gonorrhea diagnoses used a shorter timeframe (past 
12 months) that did not match well with our lifetime PID treatment variable. However, the 
strength of our study is that we used one of the few existing national data sources that 
include information on PID treatment for reproductive-aged women.
In summary, we found a decline in receipt of PID treatment and associated racial disparities 
from 1995 to 2006–10. However, in 2006–10, at least 2.5 million reproductive-aged women 
have received treatment for PID with the burden of disease falling on women of lower 
socioeconomic status. Therefore, public health and other medical efforts to reduce PID in 
these women are needed. Finally, additional research is needed to determine the cause of the 
apparent decline in PID.
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Trends in lifetime prevalence of treatment for PID among sexually experienced women in 
the United States (15–44 yrs), overall and by race/ethnicity: 1995, 2002, 2006–10
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Table 1








% (95% CI) P value % (95% CI) P value
Overall % of women who
received PID treatment
8.6% (8.0–9.2) 5.0% (4.4–5.7)
Weighted population total of





  Hispanic 8.7 (6.8–10.7) 5.1 (3.7–6.4)
  White (non-Hispanic) 8.0 (7.2–8.8) 4.7 (3.8–5.6)
  Black (non-Hispanic) 11.6 (10.1–13.1) 6.1 (4.9–7.4)
Age (years) <.0001 .0354
  15–19 4.8 (3.0–6.6) 2.6 (1.3–3.9)
  20–24 7.2 (5.8–8.6) 4.6 (3.1–6.1)
  25–29 6.9 (5.6–8.3) 5.2 (3.8–6.6)
  30–34 9.0 (7.6–10.3) 5.2 (3.8–6.6)
  35–44 10.5 (9.3–11.7) 5.6 (4.4–6.7)
Current marital status <.0001 .0046
  Married 8.5 (7.6–9.4) 4.4 (3.5–5.3)
  Cohabiting 9.5 (7.3–11.8) 6.0 (4.3–7.7)
  Formerly married 12.8 (10.7–14.9) 8.0 (5.9–10.1)
  Never married 6.7 (5.6–7.8) 4.5 (3.3–5.6)
Education level <.0001 <.0001
  < high school/no GED 10.0 (8.4–11.7) 6.7 (4.9–8.4)
  High school/GED 9.5 (8.5–10.5) 5.9 (4.7–7.1)
  Some college 8.5 (7.3–9.7) 5.9 (4.3–7.5)
  Bachelor’s degree or higher 5.9 (4.8–7.0) 1.9 (1.3–2.5)
Income-poverty ratio <.0001 <.0001
  < 150% 10.7 (9.4–12.0) 7.5 (6.3–8.8)
  150–299% 8.7 (7.6–9.7) 5.2 (3.8–6.6)
  300% or higher 7.5 (6.6–8.5) 2.5 (1.8–3.2)
Region <.0001 .9428
  Northeast 6.0 (5.0–7.0) 5.3 (3.7–6.9)
  Midwest 7.9 (6.6–9.1) 4.9 (3.8–6.0)
  South 10.0 (8.8–11.2) 5.1 (3.8–6.4)
  West 9.6 (8.2–11.0) 4.8 (3.9–5.7)
Sexual and related behaviors
Used vaginal douche* <.0001 <.0001




















% (95% CI) P value % (95% CI) P value
  Yes 12.1 (10.9–13.4) 7.7 (6.2–9.3)
  No 7.1 (6.4–7.8) 4.1 (3.4–4.7)
Age at first vaginal sex <.0001 <.0001
  < 15 years 12.5 (10.4–14.6) 10.3 (8.0–12.6)
  15–17 years 9.6 (8.7–10.4) 5.1 (4.2–6.1)
  18–19 years 6.7 (5.7–7.8) 3.0 (2.0–3.9)
  20 years or older 5.6 (4.3–7.0) 2.4 (1.4–3.5)
Number of lifetime vaginal sex
partners
<.0001 <.0001
  1 partner 5.4 (4.3–6.4) 2.4 (1.5–3.3)
  2–3 partners 6.9 (5.8–8.1) 3.9 (2.8–5.0)
  4–9 partners 9.7 (8.6–10.7) 5.8 (4.6–7.0)
  10 or more partners 15.1 (13.0–17.2) 8.0 (6.0–9.9)
Note. GED = general educational development.
*
In 1995, women were asked a yes/no question whether they regularly “douche”; in 2006–2010, women were asked how often they douched over 
the last 12 months, and were offered several response categories, including “did not douche at all.” Given the variation in question wording, a 
yes/no variable was defined for this analysis.
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Table 2
Adjusted logistic regression models: PID treatment in lifetime among sexually experienced women by race/







  Hispanic 1.15 (0.86 – 1.55) 0.96 (0.63 – 1.43)
  White (non-Hispanic) referent Referent
  Black (non-Hispanic) 1.19 (0.96 – 1.48) 0.86 (0.61 – 1.23)
Age (years)
  15–19 0.43 (0.25 – 0.71) 0.38 (0.21 – 0.68)
  20–24 0.64 (0.47 – 0.86) 0.73 (0.46 – 1.15)
  25–29 0.61 (0.47 – 0.80) 0.84 (0.60 – 1.19)
  30–34 0.76 (0.61 – 0.96) 0.89 (0.65 – 1.24)
  35–44 referent referent
Current marital status
  Married referent referent
  Cohabiting 0.89 (0.65 – 1.21) 0.90 (0.61 – 1.33)
  Formerly married 1.05 (0.82 – 1.35) 1.07 (0.77 – 1.48)
  Never married 0.83 (0.62 – 1.04) 0.88 (0.59 – 1.32)
Education level
  < high school/no GED 1.49 (1.06 – 2.11) 1.95 (1.14 – 3.35)
  High school/GED 1.32 (1.02 – 1.70) 1.89 (1.23 – 2.90)
  Some college 1.29 (1.00 – 1.67) 2.27 (1.46 – 3.55)
  Bachelor’s degree or higher referent referent
Income-poverty ratio
  < 150% 1.17 (0.92 – 1.48) 2.60 (1.79 – 3.76)
  150–299% 1.04 (0.85 – 1.27) 1.84 (1.20 – 2.82)
  300% or higher referent referent
Region
  Northeast 0.65 (0.51 – 0.84) 1.15 (0.77 – 1.72)
  Midwest 0.90 (0.70 – 1.16) 0.91 (0.66 – 1.25)
  South 1.00 (0.79 – 1.26) 0.90 (0.63 – 1.28)
  West referent referent
Sexual and related behaviors
Used vaginal douche*
  Yes 1.49 (1.24 – 1.80) 1.33 (1.01 – 1.75)
  No referent referent
Age at first vaginal sex
  < 15 years 1.59 (1.12 – 2.27) 2.57 (1.36 – 4.85)
  15–17 years 1.31 (0.98 – 1.74) 1.41 (0.80 – 2.46)


















  18–19 years 1.01 (0.74 – 1.38) 0.96 (0.55 – 1.68)
  20 years or older referent referent
Number of lifetime vaginal sex partners
  1 partner referent referent
  2–3 partners 1.23 (0.93 – 1.64) 1.35 (0.79 – 2.30)
  4–9 partners 1.67 (1.31 – 2.13) 1.76 (1.03 – 3.00)
  10 or more partners 2.61 (1.91 – 3.55) 2.10 (1.20 – 3.66)
Note. Adjustment was for variables listed in this table only. GED = general educational development.
*
In 1995, women were asked a yes/no question whether they regularly “douche”; in 2006–2010, women were asked how often they douched over 
the last 12 months, and were offered several response categories, including “did not douche at all.” Given the variation in question wording, a 
yes/no variable was defined for this analysis.
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